Repligen (RGEN) Stock Forecast & Price Target

Compare

944 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RGEN Analyst Ratings

Moderate Buy

10 Buy

5 Hold

0 Sell

Based on 15 analysts giving stock ratings to

Repligen

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RGEN Stock 12 Month Forecast

Average Price Target

$181.25

▲(47.91%Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Repligen in the last 3 months. The average price target is $181.25 with a high forecast of $207.00 and a low forecast of $150.00. The average price target represents a 47.91% change from the last price of $122.54.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"122":"$122","165":"$165","208":"$208","143.5":"$143.5","186.5":"$186.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":207,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$207.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":181.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$181.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":150,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$150.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[122,143.5,165,186.5,208],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,137.2,142.56923076923076,147.93846153846152,153.3076923076923,158.67692307692306,164.04615384615383,169.4153846153846,174.7846153846154,180.15384615384613,185.52307692307693,190.89230769230767,196.26153846153846,201.63076923076923,{"y":207,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,137.2,140.58846153846153,143.97692307692307,147.3653846153846,150.75384615384615,154.1423076923077,157.53076923076924,160.91923076923075,164.3076923076923,167.69615384615383,171.08461538461538,174.47307692307692,177.86153846153846,{"y":181.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,137.2,138.18461538461537,139.16923076923075,140.15384615384613,141.13846153846154,142.12307692307692,143.1076923076923,144.09230769230768,145.07692307692307,146.06153846153845,147.04615384615386,148.03076923076924,149.01538461538462,{"y":150,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":158.36,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":149.09,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.32,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":165.67,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":150.93,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":145.74,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":138.61,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":150.46,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":143.94,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":166.21,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":159.26,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128.5,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.2,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$207.00

Average Price Target$181.25

Lowest Price Target$150.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$134

Hold

9.35%

Upside

Reiterated

05/07/25

Repligen's overall stock score reflects a balanced view of its current financial and market conditions. Strengths include a solid balance sheet and optimistic earnings guidance, contrasted by profitability challenges and technical indicators suggesting potential price pressure. Valuation remains a concern due to negative earnings and lack of dividend yield. The earnings call provides a positive outlook, mitigating some financial and valuation concerns. The overall score suggests caution with optimism for future growth.

Ram SelvarajuH.C. Wainwright

H.C. Wainwright

$180

Buy

46.89%

Upside

Reiterated

05/05/25

Repligen's Strategic Growth and Resilience Drive Buy Rating with $180 Price Target

Robert WassermanBenchmark Co.

Benchmark Co.

―

Hold

―

Reiterated

04/30/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Atricure (NASDAQ: ATRC), SAGE Therapeutics (NASDAQ: SAGE) and Repligen (NASDAQ: RGEN)

Matt HewittCraig-Hallum

Craig-Hallum

$204

Buy

66.48%

Upside

Reiterated

04/30/25

Analysts Offer Insights on Healthcare Companies: Delcath Systems (NASDAQ: DCTH), Repligen (NASDAQ: RGEN) and CareDx (NASDAQ: CDNA)

Daniel AriasStifel Nicolaus

Stifel Nicolaus

$207

Buy

68.92%

Upside

Reiterated

04/30/25

Stifel Nicolaus Reaffirms Their Buy Rating on Repligen (RGEN)

Puneet SoudaLeerink Partners

Leerink Partners

$180→$200

Buy

63.21%

Upside

Reiterated

04/30/25

Repligen's Strong Market Position and Growth Potential Justify Buy Rating Amid Minimal Tariff Exposure

Conor McNamaraRBC Capital

RBC Capital

$202→$189

Buy

54.24%

Upside

Reiterated

04/30/25

Analysts Offer Insights on Healthcare Companies: DENTSPLY SIRONA (NASDAQ: XRAY), Repligen (NASDAQ: RGEN) and Zynex (NASDAQ: ZYXI)

Doug SchenkelWolfe Research

Wolfe Research

$160

Buy

30.57%

Upside

Upgraded

04/29/25

Repligen upgraded to Outperform from Peer Perform at Wolfe ResearchRepligen upgraded to Outperform from Peer Perform at Wolfe Research

Rachel VatnsdalJ.P. Morgan

J.P. Morgan

$200→$190

Buy

55.05%

Upside

Reiterated

04/29/25

Repligen price target lowered to $190 from $200 at JPMorganRepligen price target lowered to $190 from $200 at JPMorgan

Matt LarewWilliam Blair

William Blair

―

Buy

―

Reiterated

04/29/25

Repligen's Strong Q1 Performance and Strategic Acquisition Justify Buy Rating

Matthew Stanton, CFAJefferies

Jefferies

$165→$160

Hold

30.57%

Upside

Reiterated

04/29/25

Repligen (RGEN) PT Lowered to $914 at JefferiesJefferies analyst Matthew Stanton lowered the price target on Repligen (NASDAQ: RGEN) to $914.00 (from $936.00) while maintaining a Buy rating.

Brendan SmithTD Cowen

TD Cowen

$200

Buy

63.21%

Upside

Reiterated

04/29/25

Repligen's Strong Q1 Performance and Strategic Positioning Earns 'Buy' Rating from Analyst

Kyle Mikson CFACanaccord Genuity

Canaccord Genuity

$150

Hold

22.41%

Upside

Reiterated

04/29/25

Repligen's Fair Valuation and Cautious Growth Outlook Lead to Hold Rating

Subbu NambiGuggenheim

Guggenheim

―

Hold

―

Reiterated

04/08/25

Repligen (RGEN) Gets a Hold from Guggenheim

Daniel Markowitz CFAEvercore ISI

Evercore ISI

$155

Hold

26.49%

Upside

Initiated

03/18/25

Repligen initiated with an In Line at Evercore ISIRepligen initiated with an In Line at Evercore ISI

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$134

Hold

9.35%

Upside

Reiterated

05/07/25

Ram SelvarajuH.C. Wainwright

H.C. Wainwright

$180

Buy

46.89%

Upside

Reiterated

05/05/25

Repligen's Strategic Growth and Resilience Drive Buy Rating with $180 Price Target

Robert WassermanBenchmark Co.

Benchmark Co.

―

Hold

―

Reiterated

04/30/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Atricure (NASDAQ: ATRC), SAGE Therapeutics (NASDAQ: SAGE) and Repligen (NASDAQ: RGEN)

Matt HewittCraig-Hallum

Craig-Hallum

$204

Buy

66.48%

Upside

Reiterated

04/30/25

Analysts Offer Insights on Healthcare Companies: Delcath Systems (NASDAQ: DCTH), Repligen (NASDAQ: RGEN) and CareDx (NASDAQ: CDNA)

Daniel AriasStifel Nicolaus

Stifel Nicolaus

$207

Buy

68.92%

Upside

Reiterated

04/30/25

Stifel Nicolaus Reaffirms Their Buy Rating on Repligen (RGEN)

Puneet SoudaLeerink Partners

Leerink Partners

$180→$200

Buy

63.21%

Upside

Reiterated

04/30/25

Repligen's Strong Market Position and Growth Potential Justify Buy Rating Amid Minimal Tariff Exposure

Conor McNamaraRBC Capital

RBC Capital

$202→$189

Buy

54.24%

Upside

Reiterated

04/30/25

Analysts Offer Insights on Healthcare Companies: DENTSPLY SIRONA (NASDAQ: XRAY), Repligen (NASDAQ: RGEN) and Zynex (NASDAQ: ZYXI)

Doug SchenkelWolfe Research

Wolfe Research

$160

Buy

30.57%

Upside

Upgraded

04/29/25

Repligen upgraded to Outperform from Peer Perform at Wolfe ResearchRepligen upgraded to Outperform from Peer Perform at Wolfe Research

Rachel VatnsdalJ.P. Morgan

J.P. Morgan

$200→$190

Buy

55.05%

Upside

Reiterated

04/29/25

Repligen price target lowered to $190 from $200 at JPMorganRepligen price target lowered to $190 from $200 at JPMorgan

Matt LarewWilliam Blair

William Blair

―

Buy

―

Reiterated

04/29/25

Repligen's Strong Q1 Performance and Strategic Acquisition Justify Buy Rating

Matthew Stanton, CFAJefferies

Jefferies

$165→$160

Hold

30.57%

Upside

Reiterated

04/29/25

Repligen (RGEN) PT Lowered to $914 at JefferiesJefferies analyst Matthew Stanton lowered the price target on Repligen (NASDAQ: RGEN) to $914.00 (from $936.00) while maintaining a Buy rating.

Brendan SmithTD Cowen

TD Cowen

$200

Buy

63.21%

Upside

Reiterated

04/29/25

Repligen's Strong Q1 Performance and Strategic Positioning Earns 'Buy' Rating from Analyst

Kyle Mikson CFACanaccord Genuity

Canaccord Genuity

$150

Hold

22.41%

Upside

Reiterated

04/29/25

Repligen's Fair Valuation and Cautious Growth Outlook Lead to Hold Rating

Subbu NambiGuggenheim

Guggenheim

―

Hold

―

Reiterated

04/08/25

Repligen (RGEN) Gets a Hold from Guggenheim

Daniel Markowitz CFAEvercore ISI

Evercore ISI

$155

Hold

26.49%

Upside

Initiated

03/18/25

Repligen initiated with an In Line at Evercore ISIRepligen initiated with an In Line at Evercore ISI

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Repligen

1 Month

xxx

Success Rate

10/17 ratings generated profit

Average Return

+2.87%

reiterated a xxx

rating 29 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 58.82% of your transactions generating a profit, with an average return of +2.87% per trade.

3 Months

xxx

Success Rate

7/11 ratings generated profit

Average Return

+0.37%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 63.64% of your transactions generating a profit, with an average return of +0.37% per trade.

1 Year

Daniel AriasStifel Nicolaus

Success Rate

10/22 ratings generated profit

Average Return

+16.29%

reiterated a buy rating 29 days ago

Copying Daniel Arias's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of +16.29% per trade.

2 Years

xxx

Success Rate

7/22 ratings generated profit

Average Return

+19.89%

reiterated a xxx

rating 29 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 31.82% of your transactions generating a profit, with an average return of +19.89% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RGEN Analyst Recommendation Trends

Rating

Jan 25

Feb 25

Mar 25

Apr 25

May 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RGEN has received 20 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. RGEN average Analyst price target in the past 3 months is 181.25.

Each month's total comprises the sum of three months' worth of ratings.

RGEN Financial Forecast

RGEN Earnings Forecast

Next quarter’s earnings estimate for RGEN is $0.40 with a range of $0.36 to $0.46. The previous quarter’s EPS was $0.39. RGEN beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.24% of the time in the same period. In the last calendar year RGEN has Outperformed its overall industry.

RGEN Sales Forecast

Next quarter’s sales forecast for RGEN is $174.86M with a range of $168.80M to $179.10M. The previous quarter’s sales results were $169.17M. RGEN beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.43% of the time in the same period. In the last calendar year RGEN has Outperformed its overall industry.

RGEN Stock Forecast FAQ

What is RGEN’s average 12-month price target, according to analysts?

Based on analyst ratings, Repligen Corp’s 12-month average price target is 181.25.

What is RGEN’s upside potential, based on the analysts’ average price target?

Repligen Corp has 47.91% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RGEN a Buy, Sell or Hold?

Repligen Corp has a consensus rating of Moderate Buy which is based on 10 buy ratings, 5 hold ratings and 0 sell ratings.

What is Repligen Corp’s price target?

The average price target for Repligen Corp is 181.25. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $207.00 ,the lowest forecast is $150.00. The average price target represents 47.91% Increase from the current price of $122.54.

What do analysts say about Repligen Corp?

Repligen Corp’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of RGEN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Repligen (RGEN) Stock Forecast & Price Target

RGEN Analyst Ratings

RGEN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Repligen

RGEN Analyst Recommendation Trends

RGEN Financial Forecast

RGEN Earnings Forecast

RGEN Sales Forecast

RGEN Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts